Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: novel biomarkers of lung disease Clear all
Withdrawn No phase listed Observational

Identification of Novel Markers of Human Lung Disease

NCT02369575
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
novel biomarkers of lung disease
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 6, 2026, 9:51 PM EDT
Recruiting No phase listed Observational

Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

NCT06775106
View directory record Official record
Conditions
Pulmonary Disease, Critical Illness
Interventions
There is no intervention in this observational study
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 6, 2026, 9:51 PM EDT
Active, not recruiting Phase 2 Interventional

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

NCT03002389
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Anoro Ellipta, Arnuity Ellipta
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Keswick, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 6, 2026, 9:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 6, 2026, 9:51 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening

NCT05699213
View directory record Official record
Conditions
Lung Cancer
Interventions
Lung MRI, Blood Draw
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 6, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 6, 2026, 9:51 PM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 6, 2026, 9:51 PM EDT
Completed No phase listed Observational

Observational Study of Obstructive Lung Disease (NOVELTY)

NCT02760329
View directory record Official record
Conditions
Asthma, COPD, Chronic Obstructive Pulmonary Disease
Interventions
Blood draw, Urine, Lung function measurements, Fractional Exhaled Nitric Oxide (FENO)
Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
40
States / cities
Loma Linda, California • Long Beach, California • Roseville, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 6, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072
View directory record Official record
Conditions
Secondary Pulmonary Arterial Hypertension
Interventions
Heart Catheterization
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 6, 2026, 9:51 PM EDT
Completed Not applicable Interventional

Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

NCT01840150
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
Interventions
breath test, laboratory biomarker analysis
Procedure · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 6, 2026, 9:51 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
View directory record Official record
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 6, 2026, 9:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Developing New Ways to Detect Respiratory Impairment Early in ALS

NCT07844590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 9:51 PM EDT
Completed Early Phase 1 Interventional

A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)

NCT04193046
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Blood Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 6, 2026, 9:51 PM EDT